- Home
- PETS vs ANL Comparison
PETS vs ANL Comparison
Compare PETS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PETS | ANL |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.7M | 52.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | PETS | ANL |
|---|---|---|
| Price | $3.90 | $1.60 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $3.20 | N/A |
| AVG Volume (30 Days) | ★ 6.9M | 28.5K |
| Earning Date | 02-02-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $226,972,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.57 | $0.88 |
| 52 Week High | $6.08 | $2.99 |
Technical Indicators
Market Signals| Indicator | PETS | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 80.75 | 61.06 |
| Support Level | $1.69 | $0.88 |
| Resistance Level | $4.05 | $1.59 |
| Average True Range (ATR) | 0.34 | 0.18 |
| MACD | 0.24 | 0.04 |
| Stochastic Oscillator | 92.49 | 92.82 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.